Samsung Bioepis Analyzes US Biosimilar Market in Q4 2024 Report, Highlighting Adoption Challenges and Strategies

October 10, 2024 by No Comments

  • This year’s Q4 report newly reflects tocilizumab’s market share and Wholesale Acquisition Cost (WAC) trend analysis after biosimilars launched in Q2
  • Biosimilar Deep Dive section presents US biosimilar adoption and associated cost savings, and how payers and pharmacy benefit managers (PBMs) have optimized their biosimilar strategies for each line of business, based on a survey with 20 payers and PBMs

INCHEON, South Korea, Oct. 10, 2024 — Samsung Bioepis Co., Ltd. today released its seventh-edition Quarterly Biosimilar Market Report for the United States. The report provides updated insights into the US biosimilar market, including Average Sales Price (ASP) and Wholesales Acquisition Cost (WAC) information for 11 molecules. This includes the newly launched tocilizumab biosimilars. The report’s Biosimilar Deep Dive section features a survey of 20 payers and pharmacy benefit managers (PBMs) which highlights different biosimilar adoption strategies that payers and PBMs have implemented for each line of business (LOB; Commercial, Medicaid, and Medicare). The report also discusses how to further optimize biosimilar benefits.

“This report explores the potential savings for stakeholders through biosimilar adoption, examines the varying challenges by line of business, and discusses strategies to maximize these benefits,” said Thomas Newcomer, Vice President, Head of Market Access, US, at Samsung Bioepis. “Biosimilars have already contributed an estimated $36 billion in savings to the US healthcare market, but there is still significant room for growth. Our hope is that stakeholders will become more familiar with biosimilars and continue to embrace their potential.”

Key findings of the report include:

  • As of Aug 2024, adalimumab biosimilar market share has reached 22%, rising 4% since May 2024, highly driven by the uptake of biosimilars through private label brands
  • Two tocilizumab biosimilars (vial) entered the market in Q2 2024, one at a WAC discount of -16% ($2,220) and the other with a WAC discount of -26% ($1,960) as compared to the reference biologic ($2,656)
  • The Payer/PBM survey finds that pro-biosimilar strategies favoring biosimilars over reference biologics have started to emerge in Commercial (74%), yet still lag in Medicare (53%) and state-managed Medicaid formularies (44%). Payers cited the role of state and national policy in accelerating biosimilar adoption, such as incentivizing government programs (Medicare, Medicaid) to prefer biosimilars over reference biologics, removing grandfathering requirements that hinder biosimilar conversions, and addressing administrative burden on pharmacies and providers by viewing all biosimilars as interchangeable.

Samsung Bioepis has been publishing the Biosimilar Market report quarterly since April 2023 to provide the latest market share and price trends of all biosimilars available in the United States, after the Centers for Medicare & Medicaid Services (CMS) publishes updated quarterly ASP values for each product.

To access the full report, please visit .

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: and follow us on social media – , .

MEDIA CONTACT

Yoon Kim,

Anna Nayun Kim,